U.S. markets open in 6 hours 2 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0400-0.0100 (-0.95%)
At close: 04:00PM EST
1.0500 +0.01 (+0.96%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close1.0500
Bid0.0000 x 36200
Ask0.0000 x 34100
Day's Range1.0400 - 1.1100
52 Week Range0.9100 - 6.8700
Avg. Volume4,516,305
Market Cap134.427M
Beta (5Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings DateMar 05, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.02
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MCRB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Seres Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/08/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Business Wire

    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., January 17, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units ("RSUs") covering 22,500 shares of

  • Zacks

    Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?

    Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  • Business Wire

    Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

    CAMBRIDGE, Mass., January 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica